Current Advancements in Menopause Treatment and Management

Dear Colleagues,

Menopause, a by-product of longer human lifespans, can be a very challenging experience for some as it is often accompanied by the occurrence of vasomotor symptoms, sleep disturbance, vaginal dryness, and sexual dysfunction; 85 percent of women experience at least one of the symptoms which affects their quality of life. A greater concern is that 1 in 2 women develop osteoporosis later in menopause, and menopausal hormonal changes increase women’s risk of cardiovascular disease.

Fortunately, the last few years have witnessed a significant transformation in how we approach menopausal care. Three impactful changes shaping menopausal medicine are better information dissemination, innovation in drug development, and integration of artificial intelligence. Rapid growth in information access and open communications are helping to normalize the menopausal experience and empowering women to make informed choices. The recent movement towards more equitable and democratized care is likely to expand this progress globally.

Innovation in drug development using computer-aided drug designs have resulted in more precise contender molecules and drugs. The recent approval of the neurokinin-3 receptor antagonist Fezolinetant for vasomotor symptoms is one such example of innovation positively impacting menopausal medicine.

Despite all such progress, many questions still remain unanswered. Can we predict who will have sustained debilitating hot flashes? Who will experience a premature menopause? We hope that these questions, and many more, could be answered in the coming years using machine learning and artificial intelligence as they have the potential to analyze large volumes of data, and eventually personalize menopause management.

In this context, we cordially invite scholars and experts to contribute their original research, review articles or meta-analyses to this Special Issue, ‘Current Advancements in Menopause Treatment and Management’.

Dr. Richa Sood
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• menopause
• vasomotor symptoms
• hormone therapy
• tele-medicine
• drug innovation
• machine learning
• artificial intelligence
• cardiovascular
• osteoporosis